Literature DB >> 26668583

A susceptibility locus rs7099208 is associated with non-obstructive azoospermia via reduction in the expression of FAM160B1.

Yan Zhang1, Jing Qian2, Minghui Wu2, Mingxi Liu2, Kai Zhang3, Yuan Lin3, Xuejiang Guo2, Zuomin Zhou2, Zhibin Hu3, Jiahao Sha2.   

Abstract

Non-obstructive azoospermia (NOA) is a severe defect in male reproductive health that occurs in 1% of adult men. In a previous study, we identified that rs7099208 is located within the last intron of FAM160B1 at 10q25.3. In this study, we analysed expression Quantitative Trait Loci (eQTL) of FAM160B1, ABLIM1 and TRUB1, the three genes surrounding rs7099208. Only the expression level of FAM160B1 was reduced for the homozygous alternate genotype (GG) of rs7099208, but not for the homozygous reference or heterozygous genotypes. FAM160B1 is predominantly expressed in human testes, where it is found in spermatocytes and round spermatids. From 17 patients with NOA and five with obstructive azoospermia (OA), immunohistochemistry revealed that expression of FAM160B1 is reduced, or undetectable in NOA patients, but not in OA cases or normal men. We conclude that rs7099208 is associated with NOA via a reduction in the expression of FAM160B1.

Entities:  

Keywords:  FAM160B1; apoptosis; expression Quantitative Trait Loci; non-obstructive azoospermia; obstructive azoospermia; rs7099208

Year:  2015        PMID: 26668583      PMCID: PMC4662211          DOI: 10.7555/JBR.29.20150034

Source DB:  PubMed          Journal:  J Biomed Res        ISSN: 1674-8301


Introduction

Approximately 15%-20% of couples are infertile, with males and females suffering equally from infertility[. Non-obstructive azoospermia (NOA), a severe defect in male reproductive health, occurs in 1% of adult men[. It has been reported that a defect in the AZF region of the Y chromosome causes 10%-15% of idiopathic NOA[. However, other genetic causes of NOA remain unclear. Many gene knockouts lead to NOA in mice, but few corresponding defects have been observed in NOA men. One explanation of the relationship between risk loci and disease is that these loci are associated with mRNA expression of relevant genes[. Protein markers for disease also could have been discovered by GWAS analysis[. To investigate genetic variation in NOA patients, we recently conducted a genome-wide association study (GWAS) of NOA in Han Chinese based on genotyping 587,347 single nucleotide polymorphisms (SNPs) in 981 NOA cases and 1,657 controls[. We tested promising associations in an extended three-stage validation using 3,608 NOA cases and 5,909 controls. In the combined analysis, meta-analysis was used to combine the results of GWAS scan and three validations. We identified three risk loci associated with NOA (rs7194 at 6p21.32, rs7099208 at 10q25.3, and rs13206743 at 6p12.2)[. According to our previous study, genotype of rs7099208 in NOA patients is 43/943/3552 (Variant homozygote/Heterozygote/Wild type) and in control population is 35/1209/6312 (Variant homozygote/Heterozygote/Wild type), and minor allele frequency (MAF) of rs7099208 is 0.11 in NOA patients, which is higher than 0.08 in control population, P = 6.41x10−14[. However, it is still unknown whether rs7099208 affects mRNA expression. In this work, we tested the hypothesis that expression of risk loci related genes is altered in testes from NOA patients. Our approach examined samples from patients with NOA and obstructive azoospermia (OA), and the germ cell line of male mice.

Materials and methods

Expression Quantitative Trait Loci (eQTL)

The publicly available RNA-seq and genotyping data of 53 normal testis samples and 167 whole blood samples from the Genotype-Tissue Expression project (GTEx, http://commonfund.nih.gov/GTEx/index) were used to assess Gene Expression Quantitative Trait Loci (eQTL) for mRNA expression of FAM160B1 and genes neighbouring SNP rs7099208[.

Patients

This study was approved by the institutional review boards of each participating institution. Participants were solicited from individuals attending the First Affiliated Hospital Reproductive Centre of Nanjing Medical University for knockdown of infertility. Controls (n = 7) were defined as individuals who were diagnosed with normal spermatogenesis or OA. Patients diagnosed with NOA were the experimental group (n = 17). Six of the 17 formed the spermatid arrest sample, and the others were the spermatocyte arrest sample. For sample specific information see Supplementary Material.

Processing of testicular biopsy material

This study was approved by the ethics committees of Nanjing Medical University and was conducted in accordance with national and international guidelines. A testicular biopsy was performed in all samples (n = 24). A small incision was made in the tunica albuginea to remove tissue samples, which comprised about 3 mm3 in total.

Indirect immunohistochemistry and immunofluorescence

Indirect immunohistochemistry and immunofluorescence were performed as previously described[. To prepare sections, tissue from normal testes was fixed in Bouin fluid and dehydrated through a series of graded alcohols. The testes were then embedded in paraffin at 65 °C and sections were cut for immunohistochemistry. The testis sections were hydrated with series of graded alcohols. After endogenous peroxidase activity was blocked with 3% H2O2, non-specific binding was blocked with 10% normal goat serum. The sections were incubated overnight at 4 °C with primary antibody against FAM160B1 (Abgent) at a dilution of 1:100. After extensive washes in PBS, the sections were incubated with the secondary antibody for 1 hour at 37 °C. Next, DBA colour liquid was added to the sections and the reaction product was generated. After immunostaining, the testis sections were counterstained with hematoxylin and examined under a light microscope. For immunofluorescence, GC2 cells were fixed with 4% PFA at room temperature and 70% Ethanol at -20 °C. Cells were analysed using an epifluorescence microscope (Zeiss 710) at room temperature and Image Pro-Plus version software (Carl Zeiss, Germany) was used for analysis and imaging. Images were acquired using a 100×magnification oil lens (Zeiss). In brief, green fluorescence was excited with a 488 nm diode laser and red fluorescence with a 555 nm diode laser. Multicolour images were acquired sequentially.

PCR

Total RNA was extracted from cells with mo-FAM160B1 and mo-control tissue using an RNeasy plus Micro Kit (QIAGEN, 74034). RNA was reverse-transcribed into cDNA using a PrimeScript RT reagent Kit (Takara, DRR037S). PCR was performed with GoTaq Green Master Mix (Promega, M7122), and real-time PCR was performed with SYBR Premix EX Taq II (Takara, DRR081B). In PCR, the forward and reverse primers used were: MUS (F) GAGGGCTTGATGCTCTTGGT and (R) GCTGTATGAGTCCAACCCCC; HUM (F) GGCTGCAAAGTGCCTTACAC and (R) CGAACGATGCGATGAAGCAG. The PCR started at 95 °C for 30 seconds and was performed as follows: 28 cycles of denaturation at 95 °C for 5 seconds, annealing at 60 °C for 30 seconds and elongation at 72 °C for 30 seconds.

Western blotting assay

Samples containing 20 μg of protein (measured by the Bradford method) were used for Western blotting. Proteins from mo-FAM160B1 cells and control samples were subject to electrophoresis on a 10% sodium dodecyl sulfate polyacrylamide gel. The proteins were then transferred from the gel onto a nitrocellulose membrane (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Membranes were blocked in a solution of phosphate-buffered saline (PBS) containing 5% non-fat milk powder for 1 hour, and then incubated overnight at 4 °C with the following primary antibodies: anti- FAM160B1 (1:1,000; Abgent) and anti-β-tubulin (1:2,000; Abcam). After four 10 minutes washes in PBS, the membranes were incubated for 1 hour at 37 °C with horseradish peroxidase-conjugated secondary antibody. Specific proteins were detected using an ECL kit and AlphaImager (FluorChem5500; Alpha Innotech, San Leandro, CA).

Cell culture and morpholino knockdown

The mouse spermatocyte cell line GC2-spd (ATCC catalogue number CRL-2196, Manassas, VA, USA) was used for in vitro studies. Growth media contained 10% foetal bovine serum (GIBCO) and 5% penicillin/streptomycin, and was maintained in a 37 °C incubator in a humidified, 5% CO2 atmosphere. The knockdown was performed using morpholinos (splice blocking and translation blocking). Depending on the oligonucleotide sequence selected, morpholinos either modify pre-mRNA splicing in the nucleus, or block translation initiation in the cytosol. After incubation for 24 hours, cells were used for RT-PCR analysis, Western blotting, cell apoptosis assays and electron microscopy analysis. Morpholino sequences were splice blocking: CGTCCTAAGAAAGAACGCACACGGA; translation blocking: ACGTAAGCTTGGAGAACATCCTGTC (http://www.gene-tools.com/).

TUNEL

Apoptotic cells were examined using the terminal dideoxynucleotidyl transferase dUTP nick end labelling (TUNEL) method with the in situ cell death detection kit, POD, according to the manufacturer's protocol (Roche, Mannheim, Germany).

Electron microscopy

Testes were fixed in glutaraldehyde for 2 hours at room temperature. Ultra-thin sections (−90 nm) were cut parallel to the cell monolayer and stained in uranyl acetate and lead citrate. Nuclei of spermatocytes were randomly selected using an electron microscope (JEM-1010) and capture software (SIS VELETA CCD). The observer was blinded to the genotype.

Statistical analysis

For continuous variables, differences between two groups were tested by Student t-test or t'-test (equal variances not assumed). Differences between three groups were tested by ANOVA test or Kruskal-Wallis test (equal variances not assumed). Analyses were carried out using Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC). A two-sided P≤0.05 was considered as statistically significant.

Results

FAM160B1 correlates negatively with the homozygous alternate (GG) of rs7099208.

To investigate whether rs7099208 is associated with expression of mRNA, we analysed expression eQTL of genes surrounding rs7099208. Three genes at 10q25.3, FAM160B1, ABLIM1 and TRUB1, are candidates whose mRNA expression may be affected by rs7099208. We assessed the various genotypes of rs7099208 and the expression of FAM160B1, ABLIM1 and TRUB1 in normal human testes, using data from the Genotype-Tissue Expression project (GTEx). The eQTL data reveal that the mean mRNA expression level of FAM160B1 in testes with the homozygous alternate (GG) genotype of rs7099208 is less than that of the homozygous reference (AA) or heterozygous (AG) genotypes (). The mean expression levels of ABLIM1 and TRUB1 were not affected by the genotype of rs7099208 (). In addition, the expression level of FAM160B1 in peripheral blood was not associated with the rs7099208 genotype (P = 0.8) (). These results suggest that rs7099208 is associated with mRNA expression of gene FAM160B1 in testes.
Fig. 1

Through eQTL analysis SNP rs7099208 with gene from the Genotype-Tissue Expression project

(GTEx, http://commonfund.nih.gov/GTEx/index). SNP rs7099208 existed eQTL with gene FAM160B1(A), P = 0.05, instead of the other two: ABLIM1 (B) and TRUB1 (C). D: This eQTL was tissue-specific, existed only in the testis, while outside of comprehensive blood.

Through eQTL analysis SNP rs7099208 with gene from the Genotype-Tissue Expression project

(GTEx, http://commonfund.nih.gov/GTEx/index). SNP rs7099208 existed eQTL with gene FAM160B1(A), P = 0.05, instead of the other two: ABLIM1 (B) and TRUB1 (C). D: This eQTL was tissue-specific, existed only in the testis, while outside of comprehensive blood.

FAM160B1 was predominantly expressed in human spermatocytes and round spermatids

Using RT-PCR, expression of FAM160B1 mRNA was assessed in multiple tissue, including heart, liver, spleen, lung, kidney pancreas, brain, skeletal muscle, ovarian and testes. Expression of FAM160B1 was predominantly observed in testes (). Using immunohistochemistry, we detected FAM160B1 in male germ cells including spermatocytes and round spermatids in normal human testes (; negative controls ).
Fig. 2

FAM160B1 gene expression in Human.

A: The expression of FAM160B1 in multi-organization successively: heart, liver, spleen, lung, kidney pancreas, brain, skeletal muscle, ovarian and testes. GAPDH was used as an internal control. B-G: Immunohistochemistry of FAM160B1 in the normal Human testes. B, C, D: the negative control; E, F, G: Human testis. FAM160B1 located in post-meiotic germ cells containing spermatocytes and round spermatids.

FAM160B1 gene expression in Human.

A: The expression of FAM160B1 in multi-organization successively: heart, liver, spleen, lung, kidney pancreas, brain, skeletal muscle, ovarian and testes. GAPDH was used as an internal control. B-G: Immunohistochemistry of FAM160B1 in the normal Human testes. B, C, D: the negative control; E, F, G: Human testis. FAM160B1 located in post-meiotic germ cells containing spermatocytes and round spermatids.

Expression of FAM160B1 was reduced or undetectable in testes from NOA patients

Then, we examined FAM160B1 expression in patients within NOA and OA testes. Arrest of spermatocytes and spermatids are common phenotypes of NOA. Our NOA samples were sorted to the spermatocyte arrest group (without spermatid and mature spermatozoa but contained spermatocyte) and spermatid arrest group (without mature spermatozoa but contained round spermatid). For all five patients with OA, FAM160B1 was detected in spermatocytes and round spermatids (). Immunohistochemical analysis of 11 cases of spermatocyte arrest testes () revealed that only three of 11 showed normal positive FAM160B1 signals in spermatocyte (), and the FAM160B1 signal in spermatocyte was undetectable in four cases (). On the other hand, in spermatocyte and round spermatid (), three in six cases of spermatid arrest testes showed normal positive FAM160B1 signals (). In the remaining seven NOA samples, including spermatocytes and round spermatids arrest patients (; ), FAM160B1 signals were decreased relative to controls. These results suggest that FAM160B1 expression is associated with NOA defects ().
Fig. 3

Immunohistochemistry of FAM160B1 in the OA testes and NOA testes.

A: a-d: 4 cases of the OA. B: in spermatocyte arrest group of NOA testes (without spermatid and mature spermatozoa but contained spermatocyte). a-h: 8 cases of the spermatocyte arrest. C: in spermatid arrest group of NOA testes (without mature spermatozoa but contained round spermatid). a-d: 4 cases of the spermatid arrest. Spc: spermatocyte, rSt: round spermatid.

Table 1

Immunohistochemical analysis of FAM160B1 in testis section of NOA patients and control.

UDDecreaseNormal
OA--5
NOA(Spermatocyte Arrest)443
NOA(Spermatid Arrest)-33

UD: Undetectable

Immunohistochemistry of FAM160B1 in the OA testes and NOA testes.

A: a-d: 4 cases of the OA. B: in spermatocyte arrest group of NOA testes (without spermatid and mature spermatozoa but contained spermatocyte). a-h: 8 cases of the spermatocyte arrest. C: in spermatid arrest group of NOA testes (without mature spermatozoa but contained round spermatid). a-d: 4 cases of the spermatid arrest. Spc: spermatocyte, rSt: round spermatid. UD: Undetectable

Analysis of FAM160B1 in mouse germ cells

In mice, the expression of FAM160B1 mRNA was assessed in multiple tissue types and found predominantly in testes as the same within human (). Using immunohistochemistry, FAM160B1 was detected in spermatocytes and the later stage (; , which is available online; negative control in ). To investigate the biological role of FAM160B1 in germ cells in vitro, murine germ cell line GC2 was used. Immunofluorescence of FAM160B1 located to the cytoplasm and part of the nucleus in cell line GC2 (; negative control ).
Fig. 4

FAM160B1 gene expression in Mice.

A: The expression of FAM160B1 in multi-organization successively: heart, liver, spleen, lung, kidney pancreas, brain, skeletal muscle, ovarian and testes. Actin was used as an internal control. B-D: immunohistochemistry of FAM160B1 in the mice testes. B: the negative control. C, D: FAM160B1 showed punctate signals in germ cells including spermatocytes (Spc) and round sperm (rSt), and highly expressed in elongated sperm. E-G: Expression of FAM160B1 in GC2 cells. E: the negative control. F, G: FAM160B1 located in the cytoplasm and part of the nucleus.

FAM160B1 gene expression in Mice.

A: The expression of FAM160B1 in multi-organization successively: heart, liver, spleen, lung, kidney pancreas, brain, skeletal muscle, ovarian and testes. Actin was used as an internal control. B-D: immunohistochemistry of FAM160B1 in the mice testes. B: the negative control. C, D: FAM160B1 showed punctate signals in germ cells including spermatocytes (Spc) and round sperm (rSt), and highly expressed in elongated sperm. E-G: Expression of FAM160B1 in GC2 cells. E: the negative control. F, G: FAM160B1 located in the cytoplasm and part of the nucleus. Two morpholinos (splice blocking and translation blocking) were used to knockdown expression of FAM160B1 in GC2 cells. Following incubation with 10 µM splice blocking morpholinos for 24 hours, the number of GC2 cells decreased (). Knockdown efficiency of splice blocking reached approximately 90% at the mRNA level (). Similar results were observed after knockdown with translation blocking morpholinos (). Translation blocking of FAM160B1 also showed high efficiency ().
Fig. 5

FAM160B1 was knocked down in murine germ cell lines GC2 with morpholinos.

A, B: knockdown with splice blocking morpholinos; C: cell counting experiments between control (mo-con) and FAM160B1 (mo-fam). **P<0.01. D: Verification of the efficiency of knockdown after morpholinos blocking. Actin was used as an internal control. **P<0.01. E, F: knockdown with translation blocking morpholinos. G: cell counting experiments between control (Mo-con) and FAM160B1 (Mo-fam). **P<0.01. H: Verification of the efficiency of knockdown after morpholinos blocking. Tubulin was used as an internal control.

FAM160B1 was knocked down in murine germ cell lines GC2 with morpholinos.

A, B: knockdown with splice blocking morpholinos; C: cell counting experiments between control (mo-con) and FAM160B1 (mo-fam). **P<0.01. D: Verification of the efficiency of knockdown after morpholinos blocking. Actin was used as an internal control. **P<0.01. E, F: knockdown with translation blocking morpholinos. G: cell counting experiments between control (Mo-con) and FAM160B1 (Mo-fam). **P<0.01. H: Verification of the efficiency of knockdown after morpholinos blocking. Tubulin was used as an internal control. TUNEL analysis was performed 24 hours after knockdown with morpholinos. Positive TUNEL signals increased significantly (). Using electron microscopy, we found an accumulation of lipofuscin, lipid droplets and vacuoles in the perinuclear space of GC2 cells after inhibiting FAM160B1 (). These results suggest that FAM160B1 knockdown induced murine germ cell apoptosis.
Fig. 6

TUNEL analysis and electron microscopy after transfection with morpholinos specific to FAM160B1.

A, C: Positive signals mo-control and mo-FAM160B1 with TUNEL analysis. B, D: Larger image of A, B. E-L: Electron microscopy under morpholinos inhibiting of the two groups. E, I: the control, F, J: Larger image of E, I. G, K: in perinuclear of cells there were more lipofuscin (black arrow), lipid droplets (red arrow), vacuoles (white arrow), etc. H, L: Larger image of G, K.

TUNEL analysis and electron microscopy after transfection with morpholinos specific to FAM160B1.

A, C: Positive signals mo-control and mo-FAM160B1 with TUNEL analysis. B, D: Larger image of A, B. E-L: Electron microscopy under morpholinos inhibiting of the two groups. E, I: the control, F, J: Larger image of E, I. G, K: in perinuclear of cells there were more lipofuscin (black arrow), lipid droplets (red arrow), vacuoles (white arrow), etc. H, L: Larger image of G, K.

Discussion

Only a few cases of NOA are caused by gene mutations, for example, seipin mutation[. Due to the high incidence of both NOA and SNPs, it is reasonable to hypothesise that the main genetic cause of NOA is the collaborative effect of SNPs. In recent years, susceptibility loci associated with multiple diseases have been identified in GWAS, including breast cancer[, colorectal cancer[, endometrial cancer[, follicular lymphoma[, gastric cancer[, hepatocellular carcinoma[, Hodgkin's lymphoma[, lung cancer[, melanoma[, nasopharyngeal carcinoma[, neuroblastoma[, ovarian cancer[, pancreatic cancer[, prostate cancer[, renal cell carcinoma[, thyroid cancer[, urinary bladder cancer[ and congenital heart malformations[. In our previous study, NOA susceptibility loci were identified based on GWAS data from thousands of patients[. However, the mechanisms of disease remained unclear. Here, we analysed eQTL of genes in the region of an NOA susceptibility locus and used the data arising to identify the disease mechanism. The success of our approach suggests that GWAS could be a key to efficient characterisation of gene variations involved in NOA. Recently, we discovered several potential protein markers for cancers using GWAS analysis[. Our aim of this study is to investigate the relationship between a NOA susceptibility locus rs7099208 and genes near this region, like FAM160B1. Based on eQTL data from GTEx, we found that rs7099208 has a mild effect on expression of FAM160B1. Moreover, we demonstrated that FAM160B1 is essential for germ cell survival and reduce expression in germ cells of some NOA patients. Our study makes a connection between a mild effect of SNP (from GWAS, like rs7099208) and spermatogenic gene (like FAM160B1). It should be noticed that common SNPs (MAF>1%) widely exist in both patients and normal population. Mild effect may not cause a huge change of single gene expression, but combination of mild effects from several SNPs could contribute a severe consequence and lead to a disease (like NOA). Previous studies have shown that in NOA patients minor allele frequency (MAF) of rs7099208 is higher than the control population. Mild effect of rs7099208 may not cause a dramatic change of FAM160B1 because variant homozygote of rs7099208 exists in normal population. Although the mechanism of regulation of FAM160B1 is unclear, lack of FAM160B1 leads to germ cell apoptosis. We found the expression of FAM160B1 is changed in NOA patients. We concluded that variant homozygote of rs7099208 caused mild effect on spermatogenic gene FAM160B1. Unlike severe effect caused by gene mutation, common SNPs affect gene expression may not be contributed by singe SNP variant but combinations of mild effect of SNPs. The functional combinations of SNPs are still under discovery. Our data provide a new way to investigate spermatogenesis associated SNPs. The full understanding of FAM160B1 in spermatogenesis would be worthy to investigate in further studies.
  40 in total

1.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.

Authors:  Ellen L Goode; Georgia Chenevix-Trench; Honglin Song; Susan J Ramus; Maria Notaridou; Kate Lawrenson; Martin Widschwendter; Robert A Vierkant; Melissa C Larson; Susanne K Kjaer; Michael J Birrer; Andrew Berchuck; Joellen Schildkraut; Ian Tomlinson; Lambertus A Kiemeney; Linda S Cook; Jacek Gronwald; Montserrat Garcia-Closas; Martin E Gore; Ian Campbell; Alice S Whittemore; Rebecca Sutphen; Catherine Phelan; Hoda Anton-Culver; Celeste Leigh Pearce; Diether Lambrechts; Mary Anne Rossing; Jenny Chang-Claude; Kirsten B Moysich; Marc T Goodman; Thilo Dörk; Heli Nevanlinna; Roberta B Ness; Thorunn Rafnar; Claus Hogdall; Estrid Hogdall; Brooke L Fridley; Julie M Cunningham; Weiva Sieh; Valerie McGuire; Andrew K Godwin; Daniel W Cramer; Dena Hernandez; Douglas Levine; Karen Lu; Edwin S Iversen; Rachel T Palmieri; Richard Houlston; Anne M van Altena; Katja K H Aben; Leon F A G Massuger; Angela Brooks-Wilson; Linda E Kelemen; Nhu D Le; Anna Jakubowska; Jan Lubinski; Krzysztof Medrek; Anne Stafford; Douglas F Easton; Jonathan Tyrer; Kelly L Bolton; Patricia Harrington; Diana Eccles; Ann Chen; Ashley N Molina; Barbara N Davila; Hector Arango; Ya-Yu Tsai; Zhihua Chen; Harvey A Risch; John McLaughlin; Steven A Narod; Argyrios Ziogas; Wendy Brewster; Aleksandra Gentry-Maharaj; Usha Menon; Anna H Wu; Daniel O Stram; Malcolm C Pike; Jonathan Beesley; Penelope M Webb; Xiaoqing Chen; Arif B Ekici; Falk C Thiel; Matthias W Beckmann; Hannah Yang; Nicolas Wentzensen; Jolanta Lissowska; Peter A Fasching; Evelyn Despierre; Frederic Amant; Ignace Vergote; Jennifer Doherty; Rebecca Hein; Shan Wang-Gohrke; Galina Lurie; Michael E Carney; Pamela J Thompson; Ingo Runnebaum; Peter Hillemanns; Matthias Dürst; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Ralf Butzow; Tuomas Heikkinen; Kari Stefansson; Patrick Sulem; Sören Besenbacher; Thomas A Sellers; Simon A Gayther; Paul D P Pharoah
Journal:  Nat Genet       Date:  2010-09-19       Impact factor: 38.330

Review 2.  Understanding new genetics of male infertility.

Authors:  Maria Rosa Maduro; Dolores J Lamb
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

3.  Multiple loci identified in a genome-wide association study of prostate cancer.

Authors:  Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock
Journal:  Nat Genet       Date:  2008-02-10       Impact factor: 38.330

4.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Authors:  Gloria M Petersen; Laufey Amundadottir; Charles S Fuchs; Peter Kraft; Rachael Z Stolzenberg-Solomon; Kevin B Jacobs; Alan A Arslan; H Bas Bueno-de-Mesquita; Steven Gallinger; Myron Gross; Kathy Helzlsouer; Elizabeth A Holly; Eric J Jacobs; Alison P Klein; Andrea LaCroix; Donghui Li; Margaret T Mandelson; Sara H Olson; Harvey A Risch; Wei Zheng; Demetrius Albanes; William R Bamlet; Christine D Berg; Marie-Christine Boutron-Ruault; Julie E Buring; Paige M Bracci; Federico Canzian; Sandra Clipp; Michelle Cotterchio; Mariza de Andrade; Eric J Duell; J Michael Gaziano; Edward L Giovannucci; Michael Goggins; Göran Hallmans; Susan E Hankinson; Manal Hassan; Barbara Howard; David J Hunter; Amy Hutchinson; Mazda Jenab; Rudolf Kaaks; Charles Kooperberg; Vittorio Krogh; Robert C Kurtz; Shannon M Lynch; Robert R McWilliams; Julie B Mendelsohn; Dominique S Michaud; Hemang Parikh; Alpa V Patel; Petra H M Peeters; Aleksandar Rajkovic; Elio Riboli; Laudina Rodriguez; Daniela Seminara; Xiao-Ou Shu; Gilles Thomas; Anne Tjønneland; Geoffrey S Tobias; Dimitrios Trichopoulos; Stephen K Van Den Eeden; Jarmo Virtamo; Jean Wactawski-Wende; Zhaoming Wang; Brian M Wolpin; Herbert Yu; Kai Yu; Anne Zeleniuch-Jacquotte; Joseph F Fraumeni; Robert N Hoover; Patricia Hartge; Stephen J Chanock
Journal:  Nat Genet       Date:  2010-01-24       Impact factor: 38.330

5.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.

Authors:  Mark P Purdue; Mattias Johansson; Diana Zelenika; Jorge R Toro; Ghislaine Scelo; Lee E Moore; Egor Prokhortchouk; Xifeng Wu; Lambertus A Kiemeney; Valerie Gaborieau; Kevin B Jacobs; Wong-Ho Chow; David Zaridze; Vsevolod Matveev; Jan Lubinski; Joanna Trubicka; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Péter Rudnai; Eleonora Fabianova; Alexandru Bucur; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Joanne S Colt; Faith G Davis; Kendra L Schwartz; Rosamonde E Banks; Peter J Selby; Patricia Harnden; Christine D Berg; Ann W Hsing; Robert L Grubb; Heiner Boeing; Paolo Vineis; Françoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Eric J Duell; José Ramón Quirós; Maria-José Sanchez; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Kay-Tee Khaw; Naomi E Allen; H Bas Bueno-de-Mesquita; Petra H M Peeters; Dimitrios Trichopoulos; Jakob Linseisen; Börje Ljungberg; Kim Overvad; Anne Tjønneland; Isabelle Romieu; Elio Riboli; Anush Mukeria; Oxana Shangina; Victoria L Stevens; Michael J Thun; W Ryan Diver; Susan M Gapstur; Paul D Pharoah; Douglas F Easton; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Lars Vatten; Kristian Hveem; Inger Njølstad; Grethe S Tell; Camilla Stoltenberg; Rajiv Kumar; Kvetoslava Koppova; Olivier Cussenot; Simone Benhamou; Egbert Oosterwijk; Sita H Vermeulen; Katja K H Aben; Saskia L van der Marel; Yuanqing Ye; Christopher G Wood; Xia Pu; Alexander M Mazur; Eugenia S Boulygina; Nikolai N Chekanov; Mario Foglio; Doris Lechner; Ivo Gut; Simon Heath; Hélène Blanche; Amy Hutchinson; Gilles Thomas; Zhaoming Wang; Meredith Yeager; Joseph F Fraumeni; Konstantin G Skryabin; James D McKay; Nathaniel Rothman; Stephen J Chanock; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2010-12-05       Impact factor: 38.330

6.  Genome-wide association study identifies a common variant associated with risk of endometrial cancer.

Authors:  Amanda B Spurdle; Deborah J Thompson; Shahana Ahmed; Kaltin Ferguson; Catherine S Healey; Tracy O'Mara; Logan C Walker; Stephen B Montgomery; Emmanouil T Dermitzakis; Paul Fahey; Grant W Montgomery; Penelope M Webb; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Diether Lambrechts; Lieve Coenegrachts; Ignace Vergote; Frederic Amant; Helga B Salvesen; Jone Trovik; Tormund S Njolstad; Harald Helland; Rodney J Scott; Katie Ashton; Tony Proietto; Geoffrey Otton; Ian Tomlinson; Maggie Gorman; Kimberley Howarth; Shirley Hodgson; Montserrat Garcia-Closas; Nicolas Wentzensen; Hannah Yang; Stephen Chanock; Per Hall; Kamila Czene; Jianjun Liu; Jingmei Li; Xiao-Ou Shu; Wei Zheng; Jirong Long; Yong-Bing Xiang; Mitul Shah; Jonathan Morrison; Kyriaki Michailidou; Paul D Pharoah; Alison M Dunning; Douglas F Easton
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

7.  Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.

Authors:  Lucia Conde; Eran Halperin; Nicholas K Akers; Kevin M Brown; Karin E Smedby; Nathaniel Rothman; Alexandra Nieters; Susan L Slager; Angela Brooks-Wilson; Luz Agana; Jacques Riby; Jianjun Liu; Hans-Olov Adami; Hatef Darabi; Henrik Hjalgrim; Hui-Qi Low; Keith Humphreys; Mads Melbye; Ellen T Chang; Bengt Glimelius; Wendy Cozen; Scott Davis; Patricia Hartge; Lindsay M Morton; Maryjean Schenk; Sophia S Wang; Bruce Armstrong; Anne Kricker; Sam Milliken; Mark P Purdue; Claire M Vajdic; Peter Boyle; Qing Lan; Shelia H Zahm; Yawei Zhang; Tongzhang Zheng; Nikolaus Becker; Yolanda Benavente; Paolo Boffetta; Paul Brennan; Katja Butterbach; Pierluigi Cocco; Lenka Foretova; Marc Maynadié; Silvia de Sanjosé; Anthony Staines; John J Spinelli; Sara J Achenbach; Timothy G Call; Nicola J Camp; Martha Glenn; Neil E Caporaso; James R Cerhan; Julie M Cunningham; Lynn R Goldin; Curtis A Hanson; Neil E Kay; Mark C Lanasa; Jose F Leis; Gerald E Marti; Kari G Rabe; Laura Z Rassenti; Logan G Spector; Sara S Strom; Celine M Vachon; J Brice Weinberg; Elizabeth A Holly; Stephen Chanock; Martyn T Smith; Paige M Bracci; Christine F Skibola
Journal:  Nat Genet       Date:  2010-07-18       Impact factor: 38.330

8.  Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.

Authors:  Christopher A Haiman; Gary K Chen; William J Blot; Sara S Strom; Sonja I Berndt; Rick A Kittles; Benjamin A Rybicki; William B Isaacs; Sue A Ingles; Janet L Stanford; W Ryan Diver; John S Witte; Ann W Hsing; Barbara Nemesure; Timothy R Rebbeck; Kathleen A Cooney; Jianfeng Xu; Adam S Kibel; Jennifer J Hu; Esther M John; Serigne M Gueye; Stephen Watya; Lisa B Signorello; Richard B Hayes; Zhaoming Wang; Edward Yeboah; Yao Tettey; Qiuyin Cai; Suzanne Kolb; Elaine A Ostrander; Charnita Zeigler-Johnson; Yuko Yamamura; Christine Neslund-Dudas; Jennifer Haslag-Minoff; William Wu; Venetta Thomas; Glenn O Allen; Adam Murphy; Bao-Li Chang; S Lilly Zheng; M Cristina Leske; Suh-Yuh Wu; Anna M Ray; Anselm J M Hennis; Michael J Thun; John Carpten; Graham Casey; Erin N Carter; Edder R Duarte; Lucy Y Xia; Xin Sheng; Peggy Wan; Loreall C Pooler; Iona Cheng; Kristine R Monroe; Fredrick Schumacher; Loic Le Marchand; Laurence N Kolonel; Stephen J Chanock; David Van Den Berg; Daniel O Stram; Brian E Henderson
Journal:  Nat Genet       Date:  2011-05-22       Impact factor: 38.330

9.  A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).

Authors:  Victor Enciso-Mora; Peter Broderick; Yussanne Ma; Ruth F Jarrett; Henrik Hjalgrim; Kari Hemminki; Anke van den Berg; Bianca Olver; Amy Lloyd; Sara E Dobbins; Tracy Lightfoot; Flora E van Leeuwen; Asta Försti; Arjan Diepstra; Annegien Broeks; Jayaram Vijayakrishnan; Lesley Shield; Annette Lake; Dorothy Montgomery; Eve Roman; Andreas Engert; Elke Pogge von Strandmann; Katrin S Reiners; Ilja M Nolte; Karin E Smedby; Hans-Olov Adami; Nicola S Russell; Bengt Glimelius; Stephen Hamilton-Dutoit; Marieke de Bruin; Lars P Ryder; Daniel Molin; Karina Meden Sorensen; Ellen T Chang; Malcolm Taylor; Rosie Cooke; Robert Hofstra; Helga Westers; Tom van Wezel; Ronald van Eijk; Alan Ashworth; Klaus Rostgaard; Mads Melbye; Anthony J Swerdlow; Richard S Houlston
Journal:  Nat Genet       Date:  2010-10-31       Impact factor: 38.330

10.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

Authors:  Mario Capasso; Marcella Devoto; Cuiping Hou; Shahab Asgharzadeh; Joseph T Glessner; Edward F Attiyeh; Yael P Mosse; Cecilia Kim; Sharon J Diskin; Kristina A Cole; Kristopher Bosse; Maura Diamond; Marci Laudenslager; Cynthia Winter; Jonathan P Bradfield; Richard H Scott; Jayanti Jagannathan; Maria Garris; Carmel McConville; Wendy B London; Robert C Seeger; Struan F A Grant; Hongzhe Li; Nazneen Rahman; Eric Rappaport; Hakon Hakonarson; John M Maris
Journal:  Nat Genet       Date:  2009-05-03       Impact factor: 38.330

View more
  1 in total

Review 1.  Genetic Landscape of Nonobstructive Azoospermia and New Perspectives for the Clinic.

Authors:  Miriam Cerván-Martín; José A Castilla; Rogelio J Palomino-Morales; F David Carmona
Journal:  J Clin Med       Date:  2020-01-21       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.